Dexcom Inc. (NSDQ:DXCM) said today that the FDA approved new "artificial pancreas" software for its G4 Platinum continuous glucose monitor.
San Diego-based DexCom said its new Software 505 "features the same advanced algorithm as used in artificial pancreas research around the world."
The software makes the G4 Platinum the 1st and only CGM device with a mean absolute relative difference measurement below 10%, DexCom claimed. MARD is a standard used to measure accuracy, according to a press release.
"Patients will be able to go online and download the software, or they will receive the software preloaded onto their Dexcom receiver with new orders," CEO Terrence Gregg said in prepared remarks. "This latest software enhancement to the Dexcom G4 Platinum will make the performance level comparable to episodic blood glucose finger sticks; this is a significant step in the evolution of CGM becoming the standard-of-care over blood glucose meters for people with diabetes."
Earlier this month DexCom logged another FDA win when the federal watchdog agency approved its DexCom Smart device, which is designed to connect up to 5 smartphones with its G4 Platinum continuous glucose monitor.